[Hodgkin lymphoma].

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Hodgkin lymphoma features CD30 overexpression and NF-κB pathway activation in malignant Hodgkin/Reed-Sternberg (H/RS) cells.
• H/RS cells reside within an inflammatory and immunoinhibitory microenvironment, prompting research into modulating this milieu.
• Targeting CD30 and its signaling pathways, as well as the tumor immune microenvironment, are key therapeutic strategies.

Purpose of the Study:

• To review recent advancements in Hodgkin lymphoma treatment targeting CD30 and immune pathways.
• To highlight the efficacy of novel therapeutic agents in improving patient survival.
• To discuss the implications of these treatments for understanding Hodgkin lymphoma pathogenesis.

Main Methods:

• Review of recent clinical data and research on Hodgkin lymphoma therapeutics.
• Analysis of the molecular mechanisms underlying CD30 signaling and immune checkpoint inhibition.
• Examination of the impact of new agents on patient outcomes and disease biology.

Main Results:

• CD30 antibody-drug conjugates and immune checkpoint inhibitors have demonstrated significant efficacy.
• These novel treatments have improved survival rates for patients refractory to conventional chemotherapy.
• New agents have enhanced the understanding of PD-1 and JAK/STAT pathway involvement in Hodgkin lymphoma.

Conclusions:

• Targeted therapies like CD30 ADCs and ICIs represent major progress in Hodgkin lymphoma treatment.
• These therapies offer new hope for patients with refractory disease.
• Further research into these pathways will continue to refine treatment strategies for Hodgkin lymphoma.